Shares of Moderna slid 5.66% to $175.49 at 12:39 EST on Tuesday, after two consecutive sessions in a row of gains. NASDAQ Composite is falling 2.58% to $13,536.07, after two consecutive sessions in a row of losses. This seems, at the moment, an all-around rough trend trading session today.
Moderna’s last close was $186.02, 7.85% under its 52-week high of $189.26.
News about Moderna today
Moderna to boost Covid-19 vaccine production at Massachusetts site by 50%. According to today’s article on MarketWatch, "Shares of Moderna Inc. were down 0.3% in premarket trading on Tuesday after the company said it will double the size of its manufacturing space at its facility in Norwood, Mass., essentially allowing for a 50% increase in the production of its COVID-19 vaccine there. ", "We believe that this investment and expansion at our technology center will allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms such as prefilled syringes and lyophilized products," Moderna CEO Stéphane Bancel said in a news release. "
Moderna’s sales growth is 24182.2% for the current quarter and 6321.4% for the next. The company’s growth estimates for the present quarter and the next is 782.9% and 1983.9%, respectively.
Year-on-year quarterly revenue growth grew by 3960.8%, now sitting on 803.4M for the twelve trailing months.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $175.49 at 12:39 EST, under its 52-week high of $189.26 and way higher than its 52-week low of $30.98.
Moderna’s Moving Average
Moderna’s worth is way higher than its 50-day moving average of $143.54 and way above its 200-day moving average of $119.02.
Previous days news about Moderna
Japan to approve Moderna vaccine as soon as May 21, yomiuri says. According to Bloomberg Quint on Saturday, 1 May, "The Moderna vaccine would be the second to get approved in Japan and will be used in the nation’s large inoculation centers that will open in Tokyo and Osaka from May 24, the paper said. ", "Japan’s government will approve the use of Moderna Inc.’s Covid-19 vaccine as soon as May 21, the Yomiuri newspaper reported Saturday without attribution."
Moderna to supply up to 500 million vaccine doses to covax. According to Bloomberg Quint on Monday, 3 May, "The terms of the agreement with Gavi weren’t disclosed, though Moderna said it’s offering the vaccine at the company’s "lowest-tiered price.", "Rich countries last year snapped up vaccine supplies from Moderna and others, and the U.S. alone has already administered more than 240 million doses. "
Moderna to supply 500 million Covid-19 vaccine doses on behalf of covax. According to MarketWatch on Monday, 3 May, "We recognize that many countries have limited resources to access COVID-19 vaccines," said Moderna Chief Executive Stéphane Bancel. "
Moderna to deliver Covid-19 vaccine to hard-hit developing world. According to The Wall Street Journal on Monday, 3 May, "Covax will retain an option to purchase another 466 million doses in 2022, according to a statement by Moderna and Gavi, one of the organizations behind the vaccine aid program."
More news about Moderna.